Author/Authors :
Zacharakis Georgios نويسنده Endoscopy Unit, Limassol General Hospital and St George’s
University of London Medical School at the University of Nicosia,
Republic of Cyprus , Alzahrani Jaman نويسنده Department of Internal Medicine, University Hospital,
Prince Sattam Bin Abdulaziz University, Al Kharj, KSA
Abstract :
Introduction The recent use of new direct-acting drugs (DAAs) in
the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV
coinfected patients. Case Presentation Here, we report the case of a
47-year-old female patient with HBV/HCV coinfection who experienced HBV
reactivation during treatment with daclatasvir (DCV) and sofosbuvir
(SOF). In addition to the DAAs, Entecavir (ETV) was added to the
combined regimen with improvement in ALT levels. Conclusions Both HBV
and HCV treatment could be implemented effectively in case of
reactivation of HBV during anti-HCV treatment with DAAs. Close
monitoring of HBV DNA and ALT levels are highly recommended during DAAs
drug therapy for HCV in patients with HBV/HCV dual infection.
